Skip to content

Immersive Virtual Reality and Chronic Back Pain

The Feasibility of Immersive Virtual Reality as a Treatment for Chronic Back Pain

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04307446
Enrollment
23
Registered
2020-03-13
Start date
2021-05-01
Completion date
2023-05-31
Last updated
2023-08-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Back Pain

Brief summary

In the proposed project the investigators will evaluate the feasibility of Immersive Virtual Reality (IVR) and assess the initial effects of IVR on symptoms, affect, and tolerance to cutaneous stimuli. In this single-arm trial, the investigators will recruit 20 adults with CBP. Prior to their IVR experience, subjects will complete multiday baseline assessments using ecological momentary assessment (EMA) methodology to establish typical levels of symptoms and affect. Afterward, in a single experimental session, they will participate in two counterbalanced IVR sessions: one 10-minute and one 20-minute. Immediately after each session the investigators will measure current symptoms and affect using valid and reliable self-report questionnaires, and we will measure changes in tolerance to cutaneous stimuli using quantitative sensory testing. We will measure symptoms and affect for 72 hours after the experimental session using EMA to determine if there is a carryover. At the completion of this study, we will continue to work with stakeholders to develop clinically relevant IVR interventions for people with CBP.

Detailed description

Visit 1-Remote: Consent. Random assignment: Subjects will complete informed consent and data collection of baseline information (demographics, medical history, perceptions of pain, and experiences with VR), surveys on pain, Pain interference, fatigue, and affect. The investigators will also help the participant upload the EMA technology onto their personal phone or tablet. Subjects will then be randomly assigned to receive either the 10- minute IVR session first or the 20-minute IVR session first. Visit 1 will take between 45 and 60 minutes. Multiple Baseline EMA-Remote: Visit 2 will be scheduled 1-2 weeks later. During the time between visits the investigators will use ecological momentary assessment (EMA) technology to collect multiple measures of pain, fatigue and affect. In EMA subjects respond to prompts delivered through their cell phone or tablet (pings) with documentation of current symptoms. It is a well-recognized method to capture immediate, synchronized experiences in subjects' natural environments. During this data collection period subjects will be pinged 3x daily and asked to rate their current levels of pain, fatigue, and affect. Time to complete these responses will be 15 minutes. Visit 2-In person: pre Survey/Quantitative Sensory Testing (QST); First VR visit; post Survey/QST. The investigators will collect current pain, pain interference, fatigue and affect, and Quantitative Sensory Testing (QST). QST involves cutaneous (skin) psychophysical (semi-subjective) testing to assess sensory and pain perception pathways. QST quantifies the thresholds of detection of stimuli, the perceived intensity, and the temporal summation (changes in perception over multiple applications). These pain testing procedures are widely-accepted, non-invasive, and non-tissue damaging. The investigators will complete two types QST. Mechanical Pressure Pain Thresholds (MPPTh) will be assessed using a digital pressure algometer on the right upper trapezius and right thumb MP joint. Mechanical Temporal Summation of Pain (MTSP) will be assessed using weighted pinprick stimulators. The investigators will apply a train of 10 stimuli at the rate of 1 per second on the middle finger of the right hand, and subjects will rate the painfulness of the first, fifth, and tenth stimulus. All subjects will take part in two VR experiences (10 min and 20 min) for a total of 30-minutes in VR. After each experience subjects will rate their current pain, fatigue, and affect, and the investigators will complete QST. At the end of both sessions the subjects will rate their experiences of immersion using the Igroup Presence Questionaire, engagement using the Use Engagement Scale (UES), and simulation tolerance using the Simulator Sickness Questionnaire (SSQ). The investigators will also ask a series of open-ended questions about the participant's experiences with IVR and participation in the study. These will include questions about their enjoyment, perceptions of pain, and what they liked/did not like about the IVR experience as well as questions about the burden of being in the study. Visit 2 will take 1.5 to 2 hours Post Visit 2 EMA-Remote: Subjects will complete three more days (72 hours) of 3x a day prompts for pain, fatigue and affect. Visit 3-In person: pre Survey/Quantitative Sensory Testing (QST); Second VR visit; post Survey/QST Post Visit 3 EMA-Remote: Subjects will complete 2 more days (48 hours) of 3x a day prompts for pain, fatigue and affect.

Interventions

DEVICEImmersive Virtual Reality

Immersive Virtual Reality

Sponsors

Tufts University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
20 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

1. 20 to 75 years old 2. Any Back Pain (including neck pain) that has lasted greater than 3 months due to non-cancer related injury or illness.

Exclusion criteria

1. People with back pain primarily due to rheumatic (e.g. rheumatoid arthritis or fibromyalgia) 2. people with back pain due to central neurological disorders (e.g. stroke, multiple sclerosis, spinal cord injury) 3. has contagious disorder on the face (such as pink eye) that could be transmitted via the VR head set or has open areas on the face that would come in contact with the headset 4. had a seizure, loss of awareness, or other symptom linked to an epileptic condition 5. insufficient vision to see IVR programs 6. insufficient upper extremity coordination to operate IVR controls 7. insufficient cognitive ability to answer questionnaires or learn to use the IVR 8. unable to understand and respond to English 9. Does not own a cell phone or tablet for baseline and follow-up EMA testing.

Design outcomes

Primary

MeasureTime frameDescription
Pain Numerical Rating ScaleChange in Pain Intensity from before to immediately after interventionPain Intensity - Numerical rating scale 0 to 10 with lower score better score
Mechanical Pressure Pain Thresholds (MPPTh)Median Pre and post intervention sensitivity to pressure scores in kilogramsSensitivity to pressure will be assessed using a digital pressure algometer on the right upper trapezius and right thumb MP joint. The measures from each site were averaged to obtain an overall mean pressure score for each participant. A lower score indicates a better outcome.
Mechanical Temporal Summation of Pain (MTSP)Change in Sensitivity to pinprick from before to immediately after interventionSensitivity to pinprick was assessed using weighted pinprick stimulators. We applied a train of 10 stimuli at the rate of 1 per second on the middle finger of the right hand, and subjects rated the painfulness of the first and tenth stimulus using a 1 to 100 pain intentsity rating scale. We calculated the difference from the 1st stimuus to the 10th stimulus to calculate the sensitivity. A lower change score is a better outcome

Secondary

MeasureTime frameDescription
PANASChange in affect form before immediately after interventionTwo scales one for Positive and one for Negative Affect - Score for each scale 10 to 50 with lower score indicating less of that affect
PROMIS FatigueChange in fatigue from before to immediately after interventionFatigue on a scale of 0 to 28 with a lower score indicating less frequent experiences of fatigue

Countries

United States

Participant flow

Participants by arm

ArmCount
10 Minutes/20minutes
Subject takes part in 10 minute VR experience first and a 20 minute VR experience second Immersive Virtual Reality: Immersive Virtual Reality
12
20 Minutes/10 Minutes
Subject takes part in 20 minute VR experience first and a 10 minute VR experience second Immersive Virtual Reality: Immersive Virtual Reality
11
Total23

Withdrawals & dropouts

PeriodReasonFG000FG001
Overall StudyLost to Follow-up20

Baseline characteristics

Characteristic20 Minutes/10 Minutes10 Minutes/20minutesTotal
Age, Continuous44.8 years
STANDARD_DEVIATION 14.5
53.8 years
STANDARD_DEVIATION 18.6
49.7 years
STANDARD_DEVIATION 17.1
Length of Pain14.9 years
STANDARD_DEVIATION 15.8
12.8 years
STANDARD_DEVIATION 14.1
13.9 years
STANDARD_DEVIATION 15
Previous IVR Experience
Don't Know
0 Participants1 Participants1 Participants
Previous IVR Experience
No
6 Participants7 Participants13 Participants
Previous IVR Experience
Yes
5 Participants4 Participants9 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Asian
2 Participants0 Participants2 Participants
Race (NIH/OMB)
Black or African American
0 Participants1 Participants1 Participants
Race (NIH/OMB)
More than one race
0 Participants1 Participants1 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants
Race (NIH/OMB)
White
9 Participants10 Participants19 Participants
Region of Enrollment
United States
11 Participants12 Participants23 Participants
Sex: Female, Male
Female
5 Participants9 Participants14 Participants
Sex: Female, Male
Male
6 Participants3 Participants9 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 210 / 20
other
Total, other adverse events
0 / 210 / 20
serious
Total, serious adverse events
0 / 210 / 20

Outcome results

Primary

Mechanical Pressure Pain Thresholds (MPPTh)

Sensitivity to pressure will be assessed using a digital pressure algometer on the right upper trapezius and right thumb MP joint. The measures from each site were averaged to obtain an overall mean pressure score for each participant. A lower score indicates a better outcome.

Time frame: Median Pre and post intervention sensitivity to pressure scores in kilograms

ArmMeasureGroupValue (MEDIAN)
10 Minutes VRMechanical Pressure Pain Thresholds (MPPTh)Pre Intervention5.0 kilograms
10 Minutes VRMechanical Pressure Pain Thresholds (MPPTh)Post Intervention4.9 kilograms
20 MinutesMechanical Pressure Pain Thresholds (MPPTh)Pre Intervention5.0 kilograms
20 MinutesMechanical Pressure Pain Thresholds (MPPTh)Post Intervention5.1 kilograms
Primary

Mechanical Temporal Summation of Pain (MTSP)

Sensitivity to pinprick was assessed using weighted pinprick stimulators. We applied a train of 10 stimuli at the rate of 1 per second on the middle finger of the right hand, and subjects rated the painfulness of the first and tenth stimulus using a 1 to 100 pain intentsity rating scale. We calculated the difference from the 1st stimuus to the 10th stimulus to calculate the sensitivity. A lower change score is a better outcome

Time frame: Change in Sensitivity to pinprick from before to immediately after intervention

ArmMeasureGroupValue (MEDIAN)
10 Minutes VRMechanical Temporal Summation of Pain (MTSP)Pre Intervention8.5 units on a scale
10 Minutes VRMechanical Temporal Summation of Pain (MTSP)Post Intervention8.8 units on a scale
20 MinutesMechanical Temporal Summation of Pain (MTSP)Pre Intervention10.0 units on a scale
20 MinutesMechanical Temporal Summation of Pain (MTSP)Post Intervention8.8 units on a scale
Primary

Pain Numerical Rating Scale

Pain Intensity - Numerical rating scale 0 to 10 with lower score better score

Time frame: Change in Pain Intensity from before to immediately after intervention

ArmMeasureValue (MEAN)Dispersion
10 Minutes VRPain Numerical Rating Scale0.8 units on a scaleStandard Deviation 3.1
20 MinutesPain Numerical Rating Scale1.1 units on a scaleStandard Deviation 2.2
Secondary

PANAS

Two scales one for Positive and one for Negative Affect - Score for each scale 10 to 50 with lower score indicating less of that affect

Time frame: Change in affect form before immediately after intervention

ArmMeasureGroupValue (MEAN)Dispersion
10 Minutes VRPANASPANAS Positive-1.1 units on a scaleStandard Deviation 2.3
10 Minutes VRPANASPANAS Negative-0.7 units on a scaleStandard Deviation 2.4
20 MinutesPANASPANAS Positive-0.8 units on a scaleStandard Deviation 3.3
20 MinutesPANASPANAS Negative-0.1 units on a scaleStandard Deviation 1.9
Secondary

PROMIS Fatigue

Fatigue on a scale of 0 to 28 with a lower score indicating less frequent experiences of fatigue

Time frame: Change in fatigue from before to immediately after intervention

ArmMeasureValue (MEAN)Dispersion
10 Minutes VRPROMIS Fatigue0.1 units on a scaleStandard Deviation 1.3
20 MinutesPROMIS Fatigue-0.5 units on a scaleStandard Deviation 0.8

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026